Predictive Value of Risk Factors for Chronic Idiopathic Thrombocytopenic Purpura in Patients with Acute Type of Disease

Authors

  • Gholamreza Bahoush Department of Pediatric, Faculty of Medicine, Hematology and Oncology Ward, Ali-Asghar Children Hospital, Iran University of Medical Sciences, Tehran, Iran
  • Saeede Ghasemi Department of Pediatric, Faculty of Medicine, Ali-Asghar Children Hospital, Iran University of Medical Sciences, Tehran, Iran
  • Seyed Mohsen Razavi Clinic of Hematology and Oncology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
  • Mohammad Faranoush Pediatric Growth and Development Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran
  • Marzieh Nojoomi Department of Community Medicine, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran

DOI:

https://doi.org/10.3889/oamjms.2020.5055

Keywords:

Immune thrombocytopenia, Chronic immune thrombocytopenic purpura, Risk factor, Platelet count, Age of diagnosis, Lymphocyte

Abstract

BACKGROUND: Immune thrombocytopenic purpura (ITP) is an autoimmune disease in which autoantibodies react with platelet surface antigens and results in mild to severe thrombocytopenia due to decreased platelet count or inhibition of platelet production. Given the relatively high prevalence of ITP among children and the lack of standard diagnostic testing for the diagnosis of chronic disease, this study evaluated the predictive value of risk factors for chronic ITP in hospitalized patients.

METHODS: This prospective cohort study was performed on 65 children with ITP who referred to Ali Asghar and Rasool Akram Hospitals in Tehran, Iran, during the years 2017 and 2018. Relationships between different risk factors, including age of diagnosis, gender, white cell count, primary platelet count, mean platelet volume (MPV), history and type of the previous patient infection, FCG gene mutation, and type of FCG mutation with a chronic disease incidence were investigated using multiple logistic regression model.

RESULTS: Of 65 patients, 31 (47.69%) were male and 34 (52.31%) were female included in the study. Twenty-eight patients (43.08%) had acute ITP and 37 (56.92%) had chronic ITP. Frequency of FCG gene mutation in patients with chronic and acute type ITP was 16.36% and 7.27%, respectively (p = 0.51). No association was found between the history of the previous infection and its type with the chronic incidence of ITP. The multiple logistic regression model showed that three factors, including the absolute number of lymphocytes, age of diagnosis, and primary white blood cells (WBC) count were directly linked to chronic ITP. Furthermore, three factors of platelet, sex, and MPV were indirectly related to chronic ITP. In addition, the absolute number of lymphocytes, age of diagnosis and primary WBC count were significantly associated with chronic ITP. The receiver operating characteristic analysis showed that the cutoff rate of these factors was 0.31. Further analysis of these risk factors in comparison with the gold standard demonstrated that the diagnostic sensitivity and specificity of these risk factors for chronic ITP were 73.08% and their specificity was 88.57%, indicating the high importance and predictive power of these risk factors.

CONCLUSIONS: According to the results of this study, for the first time in Iran, six risk factors, including the absolute number of lymphocytes, age at diagnosis, sex, MPV level, platelet level at time of diagnosis, and primary WBC count were considered as the most important risk factors affecting the incidence of chronic ITP. Of course, more comprehensive studies can definitely lead to more comprehensive models.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, et al.The european hematology association roadmap for european hematology research: A consensus document. Haematologica. 2016;101(2):115-208. https://doi.org/10.3324/ haematol.2015.136739 PMid:26819058

Rahiminejad MS, Sadeghi MM, Mohammadinejad P, Sadeghi B, Abolhassani H, Firoozabadi MM, et al. Evaluation of humoral immune function in patients with chronic idiopathic thrombocytopenic purpura. Iran J Allergy Asthma Immunol. 2013;12(1):50-6. PMid:23454778

Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol. 2009;46 Suppl 2:S2-145. https://doi.org/10.1053/j.seminhematol.2008.12.005 PMid:19245930

Keihani M, Shafaeian B, Ahmadi J, Atarchi Z. The report of 28 Cases of thrombotic thrombocytopenic purpura and the risk factors and prognosis in the treatment. Tehran Univ Med J. 2000;58(4):72-8.

Gernsheimer T. Chronic idiopathic thrombocytopenic purpura: Mechanisms of pathogenesis. Oncologist. 2009;14(1):12-21. https://doi.org/10.1634/theoncologist.2008-0132 PMid:19144680

Kayal L, Jayachandran S, Singh K. Idiopathic thrombocytopenic purpura. Contemp Clin Dent. 2014;5(3):410-4. https://doi. org/10.4103/0976-237x.137976 PMid:25191085

Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129(21):2829-35. https://doi. org/10.1182/blood-2017-03-754119 PMid:28416506

Khan AM, Mydra H, Nevarez A. Clinical practice updates in the management of immune thrombocytopenia. P T. 2017;42(12):756-63. PMid:29234214

Longhurst HJ, O’Grady C, Evans G, De Lord C, Hughes A, Cavenagh J, et al. Anti-D immunoglobulin treatment for thrombocytopenia associated with primary antibody deficiency. J Clin Pathol. 2002;55(1):64-6. https://doi.org/10.1136/jcp.55.1.64 PMid:11825928

Heitink-Pollé KM, Nijsten J, Boonacker CW, de Haas M, Bruin MC. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: A systematic review and meta-analysis. Blood. 2014;124(22):3295-307. https://doi. org/10.1182/blood-2014-04-570127 PMid:25305206

ElAlfy M, Farid S, Maksoud AA. Predictors of chronic idiopathic thrombocytopenic purpura. Pediatr Blood Cancer. 2010;54(7):959-62. https://doi.org/10.1002/pbc.22481 PMid:20405514

Makis A, Gkoutsias A, Palianopoulos T, Pappa E, Papapetrou E, Tsaousi C, et al. Prognostic factors for immune thrombocytopenia outcome in greek children: A retrospective single-centered Open Access Maced J Med Sci. 2020 Aug 30; 8(B):871-877. 877 analysis. Adv Hematol. 2017;2017:7878605. https://doi. org/10.1155/2017/7878605 PMid:29362564

Bruin M, Bierings M, Uiterwaal C, Révész T, Bode L, Wiesman ME, et al. Platelet count, previous infection and FCGR2B genotype predict development of chronic disease in newly diagnosed idiopathic thrombocytopenia in childhood: Results of a prospective study. Br J Haematol. 2004;127(5):561- 7. https://doi.org/10.1111/j.1365-2141.2004.05235.x PMid:15566359

Foster CB, Zhu S, Erichsen HC, Lehrnbecher T, Hart ES, Choi E, et al. Polymorphisms in inflammatory cytokines and Fcgamma receptors in childhood chronic immune thrombocytopenic purpura: A pilot study. Br J Haematol. 2001;113(3):596-9. https:// doi.org/10.1046/j.1365-2141.2001.02807.x PMid:11380443

Pavkovic M, Petlichkovski A, Karanfilski O, Cevreska L, Stojanovic A. FC gamma receptor polymorphisms in patients with immune thrombocytopenia. Hematology. 2018;23(3):163- 8. https://doi.org/10.1080/10245332.2017.1377902 PMid:28942727

Ahmed I, Rajpurkar M, Thomas R, Chitlur M. Initial lymphocyte count and the development of persistent/chronic immune thrombocytopenic purpura. Pediatr Blood Cancer. 2010:55(3):508-11. https://doi.org/10.1002/pbc.22570 PMid:20658623

Bahoush G, Motamedi D, Vossough P. Initial lymphocyte count in patients with acute immune thrombocytopenic purpura: Can it predict persistence of the disease? Minerva Pediatr. 2014. PMid:25502733

Zeller B, Rajantie J, Hedlund-Treutiger I, Tedgård U, Wesenberg F, Jonsson OG, et al. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: Epidemiology and predictors of chronic disease. Acta Paediatr. 2005;94(2):178-84. https://doi. org/10.1111/j.1651-2227.2005.tb01887.x PMid:15981751

Jung JY, Rum AO, Kim JK, Park M. Clinical course and prognostic factors of childhood immune thrombocytopenia: Single center experience of 10 years. Korean J Pediatr. 2016;59(8):335-40. https://doi.org/10.3345/kjp.2016.59.8.335 PMid:27610182

Xu T, Li N, Jin F, Wu K, Ye Z. Predictive factors of idiopathic thrombocytopenic purpura and long-term survival in Chinese adults undergoing laparoscopic splenectomy. Surg Laparosc Endosc Percutan Tech. 2016;26(5):397-400. https://doi. org/10.1097/sle.0000000000000314 PMid:27749769

Coccia P, Ruggiero A, Attinà G, Cerchiara G, Battista A, Arena R. Chronic idiopathic thrombocytopenic purpura in children: Predictive factors and outcome. Cent Eur J Med. 2012;7(4):525- 8. https://doi.org/10.2478/s11536-012-0011-2

Robb LG, Tiedeman K. Idiopathic thrombocytopenic purpura: Predictors of chronic disease. Arch Dis Child. 1990;65(5):502-6. https://doi.org/10.1136/adc.65.5.502 PMid:2357088

Downloads

Published

2020-08-30

How to Cite

1.
Bahoush G, Ghasemi S, Razavi SM, Faranoush M, Nojoomi M. Predictive Value of Risk Factors for Chronic Idiopathic Thrombocytopenic Purpura in Patients with Acute Type of Disease. Open Access Maced J Med Sci [Internet]. 2020 Aug. 30 [cited 2024 Nov. 21];8(B):871-7. Available from: https://oamjms.eu/index.php/mjms/article/view/5055